Drugmaker

Nigeria's National Agency for Food and Drugs Administration and Control (NAFDAC) said in an alert last week that samples of the Indian-made paracetamol suspension, Para Clear, exported to Liberia last year contained the toxin ethylene glycol.

What can the inspection of select drugmaking units hope to achieve?

Experts point out that laxity on the part of regulators has resulted in substandard and adulterated drugs hitting markets in India and other countries with weak regulatory oversight.

Innova Captab files draft papers with SEBI to raise funds through IPO

The IPO will consist of a fresh issue of up to Rs 400 crore and an offer for sale of up to 9.60 million shares by shareholders and promoters

Pfizer to exit GSK's consumer health arm after spin-off

Pfizer previously signalled it would seek to sell its shareholding in Haleon, the world's largest consumer health business and home to Sensodyne toothpaste and Advil painkillers.

Novartis pays $729 million to settle US kickback charges

The Swiss drugmaker will pay $678 million to resolve claims it organized tens of thousands of sham educational events where it lavished doctors with exorbitant speaker fees, expensive dinners and alcohol to induce them to prescribe its cardiovascular and diabetes drugs more often.

Drugmaker Sanofi to raise over $11 billion via sale of Regeneron shares

Earlier this week, Regeneron had said it would repurchase about $5 billion of its shares directly from Sanofi, without altering their over-a-decade-long partnership.

Lupin gets EIR from USFDA for Nagpur plant

The health regulator had inspected the company's Nagpur manufacturing facility between January 6 and January 10, 2020, Lupin Ltd said in a statement.

Drugmaker Zydus Cadila gets USFDA nod to market generic cancer drug

The company has received final approval from the USFDA to market its product which is a generic version of Gleevec tablets, Zydus Cadila said in a statement

Drugmaker Takeda agrees to buy Shire for $64 bn

Takeda has offered the equivalent of 49 pounds in cash and stock for each share of Shire, almost 25 percent more than yesterday's closing price.

Teva CEO exits in ongoing crisis of confidence at drugmaker

A string of costly acquisitions, along with delayed drug launches, have sent Teva shares plummeting and led to calls for management and structural changes, including a possible split into separate generic and branded medicine units.

Sanofi's M&A misses frustrate some investors in drugmaker

The market is still waiting. Olivier Brandicourt's failure to land two big biotech acquisitions he was chasing has led to growing impatience among some investors.

Aurobindo shares hit 9-month low on US price fixing lawsuit

The lawsuit, filed in the US District Court for the District of Connecticut by 20 US states, also named Heritage Pharmaceuticals Inc, a company owned by India's Emcure Pharma Ltd, as a "ring leader" of the price manipulation.

US FDA finds quality control problem at Sun Pharma's Halol plant

Earlier this month, Sun said it had been informed by the US health regulator of more concerns about its plant in the western Indian state of Gujarat after a recent inspection, but details of the violations were unclear at the time.

Sun Pharma says US finds more concerns at Halol plant

The latest notice, a Form 483, was issued to Sun after the FDA completed an inspection of the Halol plant on Dec. 1, the company said. Such a notice is issued when the FDA finds that conditions at a drug plant violate US rules.

Founders of Aurobindo Pharma to sell up to $135 mn of shares

The drugmaker is selling the shares in a price range of Rs 810 to Rs 830, the term sheet showed.

Expect 10-15 launches in the US this year: Cipla

Initiatives are underway to normalise operations and the management is committed to making its EBITDA trajectory more sustainable in FY17, says Umang Vora, Global COO, Cipla.

Sanofi recalls some batches of painkiller Combiflam in India

India's Central Drugs Standard Control Organisation (CDSCO) said in notices posted on its website in February and April that it had found some batches of Combiflam to be "not of standard quality" as they failed disintegration tests.

Dr Reddy's plans bigger push on biosimilars in emerging mkt

Biosimilars are a lucrative category of medicines that is expected to generate billions of dollars in sales in the next few years, but Indian drugmakers are lagging their Western peers in launching biosimilars in developed markets.

Lupin sees more US drug approvals after disappointing Q2

Earnings of most Indian generic drugmakers, including Lupin, were hurt in recent quarters by a slowdown in the pace of approvals to launch new drugs, afLer the US Food and Drug Administration overhauled the review process.

Mylan says shareholders back Perrigo takeover

Mylan said that more than two-thirds of shareholders had backed the vote. It needed more than half of them to do so in order to pursue the takeover.

Drugmaker Shire bids $30 bn for Baxter spin-off Baxalta

Drugmaker Shire said on Tuesday it was seeking to buy Baxalta a company spun-off by Baxter International last month, for USD 30 billion to forge the leading global specialist in rare diseases.

Drugmaker GSK sees earnings growth returning in 2016

Second-quarter net income fell to 149 million pounds from 654 million pounds a year earlier, while sales rose 6 percent to 5.89 billion pounds.

Teva poised to raise its stake in Mylan: Sources

The strategy is a sign of Teva's commitment to its USD 40 billion bid for Mylan, as the latter presses on with its own USD 34 billion hostile bid for over-the-counter drug company Perrigo Company Plc.

Mylan launches generic hepatitis C drug MyHep in India

Mylan launches generic hepatitis C drug MCompany's Indian arm Mylan Pharmaceuticals has launched generic Sofosbuvir tablets in strength of 400 mg under the name MyHep in the countryyHep in India

Mylan to acquire women's healthcare biz of Famy Care

The specialty women's healthcare company‘s sales is estimated at Rs 400 crore. The acquisition is expected to close in the second half of calendar year 2015.